Néo-adjuvant chemotherapy in invasive bladder cancer

World Journal of Urology

Volumn 19, Issue 2, 2001, Pages 94-98

  Sternberg, C N ^a   Calabro F ^a  

^a Vincenzo Pansadoro Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BLADDER TUMOR; HUMAN; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 0035317156     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003450000190     Document Type: Article

References (36)

1. Herr H W ( 1992) Staging invasive bladder tumors. J Surg Oncol 51: 217-220
2. Vieweg J, Whitmore WF Jr, Herr HW (1994) The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. Cancer 74: 3020-3028
3. Montie JE (1994) Follow-up after cystectomy for carcinoma of the bladder. Urol Clin North Am 21: 639-643
4. Sternberg CN (1995) The treatment of advanced bladder cancer. Ann Oncol 6: 113-126
5. Scher HI (1990) Chemotherapy for invasive bladder tumors. Prog Clin Biol Res 353: 1-22
6. Loehrer P, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I. Raghavan D. Stuart-Harris R, Sarosdy MF, Löwe BA, Blumenstein B, Trump D (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol 10: 1066-1073
7. Logothetis CJ, Dexeus F, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990) A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastastic urothelial tumors. J Clin Oncol 8: 1050-1055
8. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ. Sogani PC, Darracott Vaughan E, Bander N, Weiselberg L, Rosado K, Smart T, Lin S-Y. Penenberg D, Fair WR, Whitmore WF (1989) M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer 64: 2448-2458
9. Scher H. Herr H. Sternberg C, Fair W. Bosl G. Morse M, Sogani P, Watson R, Dershaw D, Reuter V (1989) Neo-adjuvant chemotherapy for invasive bladder cancer: experience with the M-VAC regimen. Br J Urol 64: 250 256
10. Herr HW, Bajorin DF, Scher HI (1998) Neoadjuvant chemotherapy and bladder sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 16: 1298 1301
11. Kachnic LA, Kaufman DS, Heney N M (1997) Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15: 1022-1029
12. Sternberg CN, Pansadoro V, Calabrô F, Marini L, van Rijn A, De Carli P, Giannarelli D, Platania A, Rossetti A (1999) Neoadjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol 10: 1301-1305
13. Sternberg CN, Raghavan D, Ohi Y (1995) Néo-adjuvant and adjuvant chemotherapy in locally advanced disease: what are the effects on survival and prognosis? Int J Urol 2: 76-88
14. Donat SM, Herr HW. Bajorin DF, Fair WR. Sogani PC, Russo P, Sheinfeld J, Scher I (1996) Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. J Urol 156 (2 Pt 1): 368-71
15. Anonymous (1995) Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced Bladder Cancer Overview Collaboration. Br J Urol 75: 206-213
16. Parmar MK (1990) Neoadjuvant chemotherapy in invasive bladder cancer. Trial design. Prog Clin Biol Res 353: 115-118
17. Anonymous (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354: 53340
18. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E (1996) Five year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. J Urol 155: 1903-1906
19. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Nilsson S, Hellsten S, and members of the Nordic Urothelial Cancer Group (1999) Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer. Nordic cystectomy trial 2. Eur Urol 35[Suppl 12] : 60 (abstract 238)
20. Crawford ED, Natale RB, Burton H (1990) Southwest Oncology Group Study (8710): Trial of cystectomy alone versus neo-adjuvant M-VAC and cystectomy in patients with locally advanced bladder cancer (Intergroup Trial 0080). Prog Clin Biol Res 353: 111-114
21. Bassi P, Pagano F, Pappagallo G, Cosciani S, Lembo A, Anselmo G, Sperandio P, Signorelli G, Di Tonno F, Hurwitz E, Lavelli D, Seren M, Piazza N, Faggiano L, Fiorentino M (1998) Neo-adjuvant M-VAC of invasive bladder cancer: The G.U.O.N.E. multicenter phase III trial. Eur Urol 33 [Suppl 1]: 142 (abstract 567)
22. Abol-Enein H, El Makresh M, El Baz M, Ghoneim M (1997) Neo-adjuvant chemotherapy in treatment of invasive transitional bladder cancer: a controlled, prospective randomised study. Br J Urol 80[Suppl 2]: 49
23. Orsatti M, Curotto A, Canobbio L (1995) Alternating chemoradiotherapy in bladder cancer: a conservative approach. Int J Radiât Oncol Biol Phys 33: 173-178
24. Martinez Pineiro JA, Gonzalez Martin M, Arocena F (1995) Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: prospective randomized phase III study. J Urol 153: 964-973
25. Wallace DM, Raghavan D, Kelly KA, Sandeman TF. Conn 1C. Teriana N, Dunn J, Boulas J, Latief T(1991) Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67: 608 615
26. Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B. Carson J, Pater J, Sullivan LD (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14: 2901-2907
27. Shipley WU, Winter KA, Kaufman DS. Lee WR, Heney NM. Tester WR, Donnelly BJ, Venner PM, Ferez CA, Murray KJ, Doggett RS, True LD (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-103. J Clin Oncol 16: 3576-83
28. Splinter TA, Scher HI, Denis L, Bukowski R, Simon S, Klimberg l, Soloway M, Vogelzang NJ, van Tinteren H, Herr H (1992) The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group. J Urol 147: 606-608
29. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, Skinner DG, Benedict WF (1998) Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58: 1090-1094
30. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ (1994) Accumulation of nuclear p53 and tumor progression in bladder. N Engl J Med 331: 1259-1264
31. Schultz PK, Herr HW, Zhang Z (1994) Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients with M-VAC with 5 years follow-up. J Clin Oncol 12: 1394-1401
32. Sternberg CN, Pansadoro V, Lauretti S, Platania A, Giannarelli D, Rossetti A, De Carli P, Arena MO, Cancrini A (1995) Neo-adjuvant M-VAC (methotrexate, vinblastine, adriamycn and cisplatin) chemotherapy and bladder preservation for muscle infiltrating transitional cell carcinoma of the bladder. Urol Oncol 1: 127-133
33. Tester W, Porter A, Asbell S (1993) Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiât Oncol Biol Phys 25: 783
34. Sauer R, Birkenhake S, Kühn R, Wittekind C, Martus P, Dunst J, Schrott KM (1998) Muscle-invasive bladder cancer: transurethral resection and radiochemotherapy as an organsparing treatment option. In: Petrovich Z, Baert L, Brady LW (eds) Carcinoma of the bladder. Springer, Berlin Heidelberg New York, pp 205-214
35. Tester W, Caplan R, Heaney J (1996) Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14: 119-126
36. Housset M, Dufour B, Maulard-Durdux C, Chrétien Y, Mejean A (1997) Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer. Proc Am Soc Clin Oncol 16:319A (abstract 139)